GenePath Dx (a division of Causeway Healthcare Private Limited) is a next generation diagnostics company that provides state-of-the-art in vitro diagnostic techniques such as molecular diagnostics to the healthcare and allied communities. We are committed to providing accurate, reliable, rapid and affordable diagnostics that are relevant and actionable.
Our portfolio includes DNA and RNA based tests for Infectious Diseases, Oncology, Endocrinology, Transplantation typing, Haematology, Pharmacogenetics, and Pre-natal and pre-implantation genetic diagnostics. We use advanced, but proven, platform technologies such as quantitative/real-time polymerase chain reaction (qPCR), multiplex ligation-dependent probe amplification (MLPA), Microarrays and Sanger and Next Generation Sequencing (NGS).
At the Third National Conference of the Society for Indian Academy of Medical Genetics (SIAMG) 2016 - Dr. Meenal Agarwal gave invited lectures on "Genetic testing in dysmorphology: How to diagnose and interpret" and "Premature ovarian failure" and presented a poster on "Comparison Of Cost-Effectiveness, Quality Of Results And Overall Clinical Utility Of Commercial Versus In-House Developed Next Generation Sequencing (NGS)".
Nikhita Gogate gave an oral presentation on "Design And Clinical Application Of An In-House Developed Next Generation Sequencing (NGS) Based Assay For The CYP21A2 Gene In Congenital Adrenal Hyperplasia (CAH) Due To 21-Hydroxylase Deficiency" and a poster presentation on "Confirmation Of Small Sequence Variants Identified By Next Generation Sequencing: Is Orthogonal Testing Essential?"Vidula Sengaonkar gave a poster presentation on "Clinical Application Of An In-House Developed Amplicon Based NGS Assay For HBB Gene Analysis And Comparison With Traditional Molecular Genetic Techniques"